Deucravacitinib in plaque psoriasis: 4-year safety and efficacy results from the phase 3 POETYK PSO-1, PSO-2, and LTE trials

April W. Armstrong,[1] Mark Lebwohl,[2] Richard B. Warren,[3,4] Howard Sofen,[1,5] Akimichi Morita,[6] Shinichi Imafuku,[7] Mamitaro Ohtsuki,[8] Lynda Spelman,[9] Thierry Passeron,[10] Kim A. Papp,[11] Matthew J. Colombo,[12] John Vaile,[12] Eleni Vritzali,[12] Kim Hoyt,[12] Carolin Daamen,[12] Subhashis Banerjee,[12] Bruce Strober,[13] Diamant Thaçi,[14] Andrew Blauvelt[15]

[1]University of California Los Angeles, Los Angeles, CA, USA; [2]Icahn School of Medicine at Mount Sinai, New York, NY, USA; [3]Dermatology Centre, Northern Care Alliance NHS Foundation Trust, Manchester, UK; [4]NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK; [5]Dermatology Research Associates, Los Angeles, CA, USA; [6]Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan; [7]Fukuoka University Hospital Faculty of Medicine, Fukuoka, Japan; [8]Jichi Medical University, Tochigi, Japan; [9]Veracity Clinical Research, Brisbane, QLD, Australia; [10]Université Côte d'Azur, University Hospital of Nice, Nice, France; [11]Alliance Clinical Trials and Probity Medical Research, Waterloo, and the University of Toronto, Toronto, ON, Canada; [12]Bristol Myers Squibb, Princeton, NJ, USA; [13]Yale University School of Medicine, New Haven, and Central Connecticut Dermatology Research, Cromwell, CT, USA; [14]Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany; [15]Blauvelt Consulting, LLC, Lake Oswego, OR, USA

Introduction

- Tyrosine kinase 2 (TYK2) is an intracellular enzyme that mediates signaling of select inflammatory cytokines (eg, interleukin [IL]-23, IL-12, Type I interferons [IFNs])[1]
  - IL-23 and Type I IFNs are involved in psoriasis pathogenesis[1]
- Deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, is approved in the US, EU, and other countries for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy[2-6]
- Deucravacitinib uniquely binds to the TYK2 regulatory domain rather than to the catalytic domain where Janus kinase (JAK) 1,2,3 inhibitors bind[1,7] (**Figure 1**), driving its selectivity for TYK2 and representing the first in a new class of oral drugs

Figure 1. Mechanism of action of deucravacitinib



ATP, adenosine 5′-triphosphate; JAK, Janus kinase; TYK2, tyrosine kinase 2.

- Two global, 52-week, phase 3 trials, POETYK PSO-1 (NCT03624127) and POETYK PSO-2 (NCT03611751), in patients with moderate to severe plaque psoriasis showed that deucravacitinib 6 mg once daily (QD) was well tolerated and was significantly more efficacious than placebo and apremilast at Week 16 based on the key endpoints[8,9]:
  - PASI 75 (≥75% reduction from baseline in Psoriasis Area and Severity Index)
  - sPGA 0/1 (static Physician Global Assessment score of 0 [clear] or 1 [almost clear])
- Patients who completed the POETYK PSO-1 and PSO-2 parent trials could enroll in the ongoing POETYK long-term extension (LTE) trial (NCT04036435) and receive open-label deucravacitinib
- Clinical efficacy was previously reported to be maintained well through 3 years, with no new safety signals compared with Year 2, in deucravacitinib-treated patients who entered the POETYK LTE trial[10,11]

Objective

- To report the safety and efficacy of deucravacitinib for an additional year through 4 years (Week 208; cutoff date, November 1, 2023) in patients with moderate to severe plaque psoriasis who participated in the POETYK PSO-1, PSO-2, and LTE trials

Methods

Study designs

- In the POETYK PSO-1 and PSO-2 trials, adults with moderate to severe plaque psoriasis (PASI ≥12, sPGA ≥3, and body surface area involvement ≥10% at baseline) were randomized 1:2:1 to oral placebo, deucravacitinib 6 mg QD, or apremilast 30 mg twice daily (BID) (**Figure 2**)
- At Week 52, eligible patients were allowed to enroll in the POETYK LTE trial and receive open-label deucravacitinib 6 mg QD

Figure 2. POETYK PSO-1, PSO-2, and LTE study designs and analysis populations[a]



[a]Data reported through the POETYK LTE trial cutoff date of November 1, 2023. [b]In POETYK PSO-2, patients randomized to deucravacitinib on Day 1 who achieved PASI 75 at Week 24 were rerandomized to placebo or deucravacitinib; for patients who were rerandomized to placebo, upon relapse (≥50% loss of Week 24 PASI percent improvement from baseline), they were to cross over to deucravacitinib; however, due to a programming error, these patients continued to receive placebo until Week 52. [c]In POETYK PSO-1, patients who responded to apremilast remained on apremilast. In POETYK PSO-2, patients who responded to apremilast crossed over to placebo and were to cross over to deucravacitinib upon relapse; however, due to a programming error, these patients continued to receive placebo until Week 52. [d]Apremilast was titrated from 10 mg QD to 30 mg BID over the first 5 days of dosing.
BID, twice daily; BSA, body surface area; LTE, long-term extension; PASI, Psoriasis Area and Severity Index; PASI 75, ≥75% reduction from baseline in PASI; QD, once daily; sPGA, static Physician Global Assessment.

Analysis populations

- Safety population: patients receiving ≥1 dose of deucravacitinib at any time in the pooled parent (POETYK PSO-1 and PSO-2) and POETYK LTE trials over 4 years in the as-treated population
  - Adverse events (AEs) were ascribed to the assigned treatment when the event first occurred
- Efficacy population: patients from the pooled parent trials (POETYK PSO-1 and PSO-2) who received continuous deucravacitinib treatment from Day 1 of the parent trials through Week 208

Outcomes

- Safety outcomes: AEs, serious AEs (SAEs), deaths, AEs leading to treatment discontinuation, and AEs of interest through the last data cutoff date of November 1, 2023
- Efficacy outcomes: achievement of PASI 75, ≥90% reduction from baseline in PASI (PASI 90), 100% reduction from baseline in PASI (PASI 100), sPGA 0/1, and sPGA 0

Statistical analysis

- Efficacy and safety were analyzed through the data cutoff date of November 1, 2023 (Week 208, 4 years)
- Safety data were reported as exposure-adjusted incidence rate (EAIR)/100 person-years (PY) and calculated as 100 * (number of patients with an AE) / (total exposure time for all patients at risk [time to initial AE occurrence for patients with AE + total exposure time for patients without AE])
- In addition to observed values, two methods of imputation for missing data were used as sensitivity analyses for efficacy
  - **Treatment failure rules (TFR)[12]:** patients who discontinued treatment due to lack of efficacy or worsening of psoriasis were imputed as nonresponders; all other missing data were not imputed
  - **Modified nonresponder imputation (mNRI)[13]:** patients who either discontinued prior to Week 208 or reached Week 208 were included; patients with missing data who discontinued treatment due to worsening of psoriasis were imputed as nonresponders; all other missing data were imputed by multiple imputation

Results

Patients

- Baseline demographics and disease characteristics for patients who received continuous deucravacitinib from Day 1 (n = 513) are presented in **Table 1**

Table 1. Baseline patient demographics and disease characteristics for the efficacy population

Parameter	Patients receiving continuous deucravacitinib[a] (n = 513)
Age, mean (SD), y	46.9 (13.3)
Weight, mean (SD), kg	89.9 (22.2)
Body mass index, mean (SD), kg/m²	30.3 (7.0)
Female, n (%)	159 (31.0)
Race, n (%)	
White	440 (85.8)
Asian	64 (12.5)
Black or African American	5 (1.0)
Other	4 (0.8)
Disease duration, mean (SD), y	18.8 (12.6)
Prior systemic therapy, n (%)	300 (58.5)
Prior systemic biologic	191 (37.2)
Prior systemic non-biologic	206 (40.2)
Systemic therapy naive, n (%)	213 (41.5)
PASI score, mean (SD)	21.1 (7.9)
sPGA score, n (%)	
3 (moderate)	401 (78.2)
4 (severe)	112 (21.8)
BSA involvement, mean (SD), %	26.9 (15.8)

[a]Randomized to deucravacitinib in the parent trials and entering the POETYK LTE trial.
BSA, body surface area; PASI, Psoriasis Area and Severity Index; SD, standard deviation; sPGA, static Physician Global Assessment.

Deucravacitinib exposure

- Exposure data through 4 years are shown in **Table 2**

Table 2. Deucravacitinib exposure of the safety population through Week 208 (4 years)

Exposure	Deucravacitinib 6 mg QD (n = 1519)
Total exposure, PY	**4392.8**
Median (min, max) exposure, days	1298.0 (1, 1893)
≥4 months of exposure, n (%)	1407 (92.6)
≥12 months of exposure, n (%)	1203 (79.2)
≥24 months of exposure, n (%)	1050 (69.1)
≥36 months of exposure, n (%)	906 (59.6)
≥48 months of exposure, n (%)	542 (35.7)

This represents the pooled POETYK PSO-1, PSO-2, and LTE population through the cutoff date of November 1, 2023.
LTE, long-term extension; max, maximum; min, minimum; PY, person-years; QD, once daily.

Overall safety

- A cumulative safety summary is presented in **Table 3**
- Aside from higher rates of COVID-19 due to the concurrent global pandemic, incidence rates of AEs (EAIR = n/100 PY) decreased from 1 year to 4 years

Table 3. Cumulative safety summary through 1 year and 4 years (as-treated population)

AE category	Cumulative through 1 year[a] (POETYK PSO-1 + PSO-2) Deucravacitinib (n = 1364) Total PY = 969.0		Cumulative through 4 years[b] (POETYK PSO-1 + PSO-2 + LTE) Deucravacitinib (n = 1519) Total PY = 4392.8	
	1-Year cumulative n (%)	EAIR/100 PY (95% CI)	4-Year cumulative n (%)	EAIR/100 PY (95% CI)
AEs	995 (72.9)	**229.2 (215.4-243.9)**	1301 (85.6)	**131.7 (124.6-139.0)**
SAEs	55 (4.0)	**5.7 (4.4-7.4)**	205 (13.5)	**5.0 (4.4-5.8)**
Discontinued treatment due to AEs	43 (3.2)	**4.4 (3.3-5.9)**	97 (6.4)	**2.2 (1.8-2.7)**
Deaths	2 (0.1)[c]	**0.2 (0.1-0.8)**	11 (0.7)[d]	**0.3 (0.1-0.4)**
Most common AEs (EAIR ≥5/100 PY)				
Nasopharyngitis	229 (16.8)	**26.1 (23.0-29.8)**	343 (22.6)	**9.7 (8.7-10.8)**
Upper respiratory tract infection	124 (9.1)	**13.4 (11.3-16.0)**	240 (15.8)	**6.1 (5.4-6.9)**
Headache	80 (5.9)	**8.5 (6.8-10.5)**	117 (7.7)	**2.8 (2.3-3.4)**
Diarrhea	69 (5.1)	**7.3 (5.7-9.2)**	99 (6.5)	**2.4 (1.9-2.9)**
Arthralgia	55 (4.0)	**5.7 (4.4-7.4)**	117 (7.7)	**2.8 (2.3-3.4)**
COVID-19[e]	5 (0.4)	**0.5 (0.1-1.2)**	321 (21.1)	**8.3 (7.4-9.3)**

Not all patients were receiving deucravacitinib 6 mg QD continuously throughout this period. Total PY corresponds to the total exposure time to deucravacitinib during the indicated time period. [a]This represents the pooled patient population of POETYK PSO-1 and PSO-2 (Weeks 0-52). [b]This represents the pooled POETYK PSO-1, PSO-2, and LTE population through the cutoff date of November 1, 2023. [c]In POETYK PSO-1 and PSO-2 through 1 year, 1 patient discontinued deucravacitinib after 4 days of treatment due to prohibited medication (leflunomide) and died 9 days later reportedly due to heart failure and sepsis, with no medical records available. Another death occurred between Weeks 16 and 52 and was due to hepatocellular carcinoma in a patient with a history of hepatitis C virus infection and liver cirrhosis. Both deaths were considered unrelated to treatment by the investigator. [d]After Week 52, 7 deaths were due to COVID-19 (all in patients with risk factors for severe disease; 2 deaths were considered related to treatment by the investigator and the other 5 deaths were considered unrelated to treatment by the investigator). One patient with cardiovascular risk factors died due to a ruptured aortic aneurysm, which was considered unrelated to treatment by the investigator. One patient died due to sudden death, which was considered not related to treatment by the investigator. [e]POETYK PSO-1, PSO-2, and LTE trials were conducted during the COVID-19 pandemic.
AE, adverse event; CI, confidence interval; EAIR, exposure-adjusted incidence rate; LTE, long-term extension; PY, person-years; QD, once daily; SAE, serious adverse event.

AEs of interest

- The EAIRs of AEs of interest from the 4-year cumulative period (**Table 4**) remained comparable to findings from long-term clinical safety studies, disease registries, and real-world claims data of other approved psoriasis treatments
- The rate of serious infections was higher at 4 years than at 1 year; the peak of the global COVID-19 pandemic occurred during Years 2 and 3 of the POETYK LTE trial
  - When COVID-19 was excluded from the 4-year analysis, the rate of serious infections was lower at 4 years (EAIR/100 PY [95% confidence interval (CI)], 0.8 [0.6-1.1])
  - The rate of serious infections with COVID-19 excluded was comparable to long-term clinical safety studies of other psoriasis treatments (0.97-1.1/100 PY)
- The rate of herpes zoster decreased from Year 1 to Year 4
- Incidence rates for adjudicated major adverse cardiovascular events (MACE) were low and comparable through 1 year and 4 years
  - Rates of MACE with deucravacitinib treatment through 4 years were comparable to long-term clinical safety studies of other psoriasis treatments (0.3-0.4/100 PY)
- Incidence rates for malignancies were low and comparable through 1 year and 4 years
  - The rate of malignancy (excluding nonmelanoma skin cancer [NMSC]) with deucravacitinib through 4 years was consistent with other trials (0.4-0.6/100 PY)
  - The rate of NMSC in patients treated with deucravacitinib was consistent with other trials (0.3-0.5/100 PY), and the ratio of basal cell to squamous cell carcinoma remained at least 2:1
- No venous thromboembolism (VTE) or lymphoma events were observed in Year 3 or Year 4

Table 4. Cumulative AEs of interest through 1 year and 4 years (as-treated population)

AE category	Cumulative through 1 year[a] (POETYK PSO-1 + PSO-2) Deucravacitinib (n = 1364) Total PY = 969.0		Cumulative through 4 years[b] (POETYK PSO-1 + PSO-2 + LTE) Deucravacitinib (n = 1519) Total PY = 4392.8	
	1-Year cumulative n (%)	EAIR/100 PY (95% CI)	4-Year cumulative n (%)	EAIR/100 PY (95% CI)
Serious infections	17 (1.2)	**1.7 (1.1-2.8)**	85 (5.6)	**2.0 (1.6-2.5)**
Serious COVID-19 infections				
Serious COVID-19	2 (0.1)	**0.2 (0.1-0.8)**	38 (2.5)	**0.9 (0.6-1.2)**
Serious COVID-19 pneumonia	0	**0**	16 (1.1)	**0.4 (0.2-0.6)**
Herpes zoster (non-serious)				
Herpes zoster[c]	8 (0.6)	**0.8 (0.4-1.6)**	24 (1.6)	**0.6 (0.4-0.8)**
Ophthalmic herpes zoster[d]	1 (0.1)	**0.1 (0.0-0.7)**	1 (0.1)	**0.0 (0.0-0.1)**
MACE[e]	3 (0.2)	**0.3 (0.1-0.9)**	14 (0.9)	**0.3 (0.2-0.5)**
VTE[f]	2 (0.1)	**0.2 (0.1-0.8)**	3 (0.2)	**0.1 (0.0-0.2)**
Malignancies	10 (0.7)	**1.0 (0.5-1.9)**	39 (2.6)	**0.9 (0.6-1.2)**
NMSC	7 (0.5)	**0.7 (0.3-1.5)**	18 (1.2)	**0.4 (0.2-0.7)**
Basal cell carcinoma	4 (0.3)	**0.4 (0.2-1.1)**	13 (0.9)	**0.3 (0.2-0.5)**
Squamous cell carcinoma[g]	2 (0.1)	**0.2 (0.1-0.8)**	5 (0.3)	**0.1 (0.0-0.3)**
Malignancies excluding NMSC	3 (0.2)	**0.3 (0.1-0.9)**	22 (1.4)[h]	**0.5 (0.3-0.8)**
Lymphoma	1 (0.1)	**0.1 (0.0-0.7)**	3 (0.2)	**0.1 (0.0-0.2)**
Hodgkin's disease	1 (0.1)	**0.1 (0.0-0.7)**	1 (0.1)	**0.0 (0.0-0.1)**
Leukemia	0	**0**	1 (0.1)	**0.0 (0.0-0.1)**

Not all patients were receiving deucravacitinib 6 mg QD continuously throughout this period. Total PY corresponds to the total exposure time to deucravacitinib during the indicated time period. [a]This represents the pooled patient population of POETYK PSO-1 and PSO-2 (Weeks 0-52). [b]This represents the pooled POETYK PSO-1, PSO-2, and LTE population through the cutoff date of November 1, 2023. [c]One patient who was coded as having herpes zoster had corneal/ocular disease related to herpes virus infection diagnosed by an ophthalmologist with a positive qualitative chickenpox virus antigen (epithelial cells). [d]One patient who was coded as having ophthalmic herpes zoster with swelling of eyelids was referred for ophthalmology consultation, which was noted as normal; there was no corneal/ocular disease related to herpes virus infection [e]MACE were adjudicated and were defined as nonfatal stroke, nonfatal myocardial infarction, or cardiovascular death. MACE in deucravacitinib-treated patients through 1 year: cardiac failure leading to death, cerebrovascular accident, myocardial infarction. Through 4 years: acute myocardial infarction (n = 5), cerebrovascular accident (n = 2), myocardial infarction (n = 2), aortic aneurysm rupture, cardiac arrest, cardiac failure leading to death, cerebral hemorrhage, ischemic stroke, sudden death. [f]VTE was defined as deep vein thrombosis and pulmonary embolism. VTE events in deucravacitinib-treated patients through 1 year: deep vein thrombosis; pulmonary embolism. Through 4 years: deep vein thrombosis (n = 2), pulmonary embolism. The second deep vein thrombosis event occurred in Year 2. [g]Includes preferred terms of squamous cell carcinoma, squamous cell carcinoma of skin, and Bowen's disease. [h]Includes events of breast cancer (n = 2), invasive ductal breast carcinoma, intraductal proliferative breast lesion, lung adenocarcinoma (n = 2), colon cancer (n = 2), metastatic colon cancer, adenocarcinoma of colon, colorectal cancer, pancreatic carcinoma, hepatocellular carcinoma, B-cell lymphoma, nodal marginal zone B-cell lymphoma, Hodgkin's disease, acute promyelocytic leukemia, malignant melanoma (n = 2), esophageal carcinoma, prostate cancer, squamous cell carcinoma of the tongue, and squamous cell carcinoma of the oral cavity.
AE, adverse event; CI, confidence interval; EAIR, exposure-adjusted incidence rate; LTE, long-term extension; MACE, major adverse cardiovascular event; NMSC, nonmelanoma skin cancer; PY, person-years; QD, once daily; VTE, venous thromboembolism.

Efficacy

- PASI 75 (**Figure 3**), PASI 90 (**Figure 4**), and PASI 100 (**Figure 5**) response rates were sustained well from Week 52 (beginning of the POETYK LTE trial) through 4 years
- sPGA 0/1 (**Figure 6**) and sPGA 0 (**Figure 7**) response rates were sustained well from Week 52 (beginning of the POETYK LTE trial) through 4 years

Figure 3. PASI 75 response rates in the efficacy population



[a]TFR analysis captures discontinuations coded as "lack of efficacy." [b]For mNRI analyses, at timepoints where there were no missing data, 95% CI was obtained using the Clopper-Pearson method based on the observed data. [c]Data callouts represent the response rate (95% CI).
CI, confidence interval; LTE, long-term extension; mNRI, modified nonresponder imputation; PASI 75, ≥75% reduction from baseline in Psoriasis Area and Severity Index; TFR, treatment failure rules.

Figure 4. PASI 90 response rates in the efficacy population



[a]TFR analysis captures discontinuations coded as "lack of efficacy." [b]For mNRI analyses, at timepoints where there were no missing data, 95% CI was obtained using the Clopper-Pearson method based on the observed data. [c]Data callouts represent the response rate (95% CI).
CI, confidence interval; LTE, long-term extension; mNRI, modified nonresponder imputation; PASI 90, ≥90% reduction from baseline in Psoriasis Area and Severity Index; TFR, treatment failure rules.

Figure 5. PASI 100 response rates in the efficacy population



[a]TFR analysis captures discontinuations coded as "lack of efficacy." [b]For mNRI analyses, if there are no missing data (ie, no imputed values in the dataset), 95% CI was obtained using the Clopper-Pearson method based on the observed data. [c]Data callouts represent the response rate (95% CI).
CI, confidence interval; LTE, long-term extension; mNRI, modified nonresponder imputation; PASI 100, 100% reduction from baseline in Psoriasis Area and Severity Index; TFR, treatment failure rules.

Figure 6. sPGA 0/1 response rates in the efficacy population



[a]TFR analysis captures discontinuations coded as "lack of efficacy." [b]For mNRI analyses, at timepoints where there were no missing data, 95% CI was obtained using the Clopper-Pearson method based on the observed data. [c]Data callouts represent the response rate (95% CI).
CI, confidence interval; LTE, long-term extension; mNRI, modified nonresponder imputation; sPGA 0/1, static Physician Global Assessment score of 0 (clear) or 1 (almost clear) with a ≥2-point improvement from baseline; TFR, treatment failure rules.

Figure 7. sPGA 0 response rates in the efficacy population



[a]TFR analysis captures discontinuations coded as "lack of efficacy." [b]For mNRI analyses, if there are no missing data (ie, no imputed values in the dataset), 95% CI was obtained using the Clopper-Pearson method based on the observed data. [c]Data callouts represent the response rate (95% CI).
CI, confidence interval; LTE, long-term extension; mNRI, modified nonresponder imputation; sPGA 0, static Physician Global Assessment score of 0 (clear) with a ≥2-point improvement from baseline; TFR, treatment failure rules.

Conclusions

- Deucravacitinib demonstrated a consistent safety profile through 4 years with >4000 PY of exposure and with no increases in AE or SAE rates over time and no emergence of any new safety signals, except for increased rates of COVID-19 due to the concurrent global pandemic
  - Rates of serious infections (minus COVID-19), malignancies, and MACE through 4 years were comparable with what has been observed with approved psoriasis treatments in clinical trials and real-world databases
- PASI 75, PASI 90, PASI 100, sPGA 0/1, and sPGA 0 responses were sustained through 4 years in over 500 patients treated continuously with deucravacitinib from Day 1 in the parent trials
- These data support the long-term safety and durable efficacy profile through 4 years of treatment with deucravacitinib, a first-in-class TYK2 inhibitor treatment for psoriasis

References

1. Burke JR, et al. *Sci Transl Med*. 2019;11:eaaw1736. **2.** Sotyktu [package insert]. Princeton, NJ, USA: Bristol Myers Squibb; September 2022. **3.** Sotyktu [EU summary of product characteristics]. Dublin, Ireland: Bristol Myers Squibb EEIG; December 2023. **4.** Sotyktu [package insert]. Tokyo, Japan: Bristol Myers Squibb K.K.; September 2022. **5.** Sotyktu [product monograph]. Montreal, QC, Canada: Bristol Myers Squibb Canada Co.; November 2022. **6.** Sotyktu [product information]. Mulgrave, VIC, Australia: Bristol Myers Squibb Australia Pty. Ltd.; December 2022. **7.** Wrobleski ST, et al. *J Med Chem*. 2019;62:8973-8995. **8.** Armstrong AW, et al. *J Am Acad Dermatol*. 2023;88:29-39. **9.** Strober B, et al. *J Am Acad Dermatol*. 2023;88:40-51. **10.** Lebwohl M, et al. *Br J Dermatol*. 2024;190:668-679. **11.** Armstrong, A, et al. Presented at the 32nd EADV Congress; 11-14 October 2023; Berlin, Germany. **12.** Reich K, et al. *Br J Dermatol*. 2021;185:1146-1159. **13.** Papp K, et al. *Br J Dermatol*. 2021;185:1135-1145.

Acknowledgments

- This study was sponsored by Bristol Myers Squibb and was supported by the NIHR Manchester Biomedical Research Centre (NIHR203308)
- We thank Julie Scotto, MPH, for her contribution to the analysis of the epidemiological data included herein
- Writing and editorial assistance was provided by Kimberly MacKenzie, PhD, of Peloton Advantage, LLC, an OPEN Health company, funded by Bristol Myers Squibb

Disclosures

AWA: Research investigator, scientific advisor, and/or speaker: AbbVie, Almirall, Arcutis, ASLAN, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Dermira, EPI Health, Incyte, Janssen, Leo Pharma, Lilly, Mindera Health, Nimbus, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, Sun Pharma, and UCB. **ML:** Research funds on behalf of Mount Sinai: AbbVie, Amgen, Arcutis, Avotres, Boehringer Ingelheim, Cara Therapeutics, Dermavant, Incyte, Janssen, Lilly, Ortho Dermatologics, Regeneron, and UCB; Consultant: Almirall, AltruBio, AnaptysBio, Arcutis, Avotres, Boehringer Ingelheim, Brickell Biotech, Bristol Myers Squibb, Castle Biosciences, Celltrion, CorEvitas Psoriasis Registry, Dermavant, EPI Health, Evommune, Forte Biosciences, Galderma, Genentech, Incyte, Leo Pharma, Meiji Seika Pharma, Mindera Health, Pfizer, Seanergy, Strata, Trevi, and Verrica. **RBW:** Research grants: AbbVie, Almirall, Amgen/Celgene, Janssen, Leo Pharma, Lilly, Novartis, Pfizer, and UCB; Consulting fees: AbbVie, Almirall, Amgen/Celgene, Astellas, Boehringer Ingelheim, DICE Therapeutics, GSK, Janssen, Leo Pharma, Lilly, Novartis, Pfizer, Sanofi, UCB, and Union. **HS:** Clinical investigator: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Leo Pharma, Lilly, Novartis, and Sun Pharma. **AM:** Honorarium as meeting chair/lecturer: AbbVie, Ayumi, Boehringer Ingelheim Japan, Celgene K.K., Eisai, Eli Lilly Japan K.K., Inforward, Janssen Pharmaceutical K.K., Kyowa Kirin, Maruho Co., Mitsubishi Tanabe Pharma, Nippon Kayaku, Novartis Pharma K.K., Taiho Pharmaceutical, Torii Pharmaceutical, and Ushio; Funding: AbbVie G.K., Eisai, Eli Lilly Japan K.K., Kyowa Hakko Kirin, Leo Pharma K.K., Maruho, Mitsubishi Tanabe Pharma, Novartis Pharma K.K., Taiho Pharmaceutical, and Torii Pharmaceutical; Consulting fees: AbbVie GK, Boehringer Ingelheim Japan, Bristol Myers Squibb, Celgene K.K., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Janssen Pharmaceutical K.K., Kyowa Kirin, Maruho, Mitsubishi Tanabe Pharma, Nichi-Iko Pharmaceutical, Nippon Kayaku, Novartis Pharma K.K., Pfizer Japan, Sun Pharma, Torii Pharmaceutical, and UCB Japan. **SI:** Grants and/or personal fees: AbbVie, Alexion Pharma, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eisai, Janssen, GSK, Kaken, Kyowa Kirin, Leo Pharma, Lilly, Maruho, Novartis, Sun Pharma, Taiho Yakuhin, Torii Yakuhin, and UCB. **MO:** Honoraria and/or research grants: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eisai, Janssen, Kyowa Kirin, Leo Pharma, Lilly, Maruho, Mitsubishi Tanabe Pharma, Nichi-Iko, Nippon Kayaku, Novartis, Pfizer, Sanofi, Sun Pharma, Taiho Pharmaceutical, Torii Pharmaceutical, and UCB. **LS:** Consultant, paid investigator, and/or speaker: AbbVie, Amgen, Anacor, Ascend, Astellas, AstraZeneca, Blaze Bioscience, Boehringer Ingelheim, Botanix, Bristol Myers Squibb, Connect Biopharma, Celgene, Genesis Care, Dermira, Enkang, Equillium, Evelo Biosciences, Genesis Care, Galderma, Genentech, GSK, Hexima, Incyte, InflaRx GmbH, Invion, Janssen, Kiniksa, Kobio Labs, Leo Pharma, LG Chem, Eli Lilly, Lipidio Pharma, Mayne, Medimmune, Merck, Merck-Serono, Novartis, Nektar Therapeutics, Olix, Otsuka, Pfizer, Phosphagenics, Photon MD, Principia, Regeneron, Ribon, Samumed, Sanofi Genzyme, SHR, Sun Pharma, Takeda, UCB, and Zai Lab. **TP:** Advisory board and consulting fees: AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Galderma, Incyte, Janssen, Leo Pharma, Lilly, Novartis, Pfizer, Sanofi Genzyme, Sun Pharma, and UCB. **KAP:** Consultant: AbbVie, Acelyrin, Akros, Amgen, Aralez, Arcutis, Avillion, Bausch Health/Valeant, Boehringer Ingelheim, Bristol Myers Squibb, Can-Fite Biopharma, Celltrion, Coherus, Dermavant, Dermira, DICE Therapeutics, Dow Pharma, Evelo Biosciences, Forbion, Galderma, Incyte, Janssen, Kyowa Kirin, Leo Pharma, Lilly, Meiji Seika Pharma, Merck, Mitsubishi Pharma, Novartis, Pfizer, Regeneron, Reistone, Roche, Sanofi Aventis/Genzyme, Sandoz, Sun Pharma, Takeda, UCB, vTv Therapeutics, and Xencor; Speakers bureau: AbbVie, Amgen, Bausch Health/Valeant, Galderma, Incyte, Janssen, Kyowa Kirin, Leo Pharma, Lilly, Merck, Novartis, Pfizer, and Sanofi Genzyme; Clinical research grants: AbbVie, Akros, Amgen, Anacor, Arcutis, Avillion, Bausch Health/Valeant, Boehringer Ingelheim, Bristol Myers Squibb, Can-Fite Biopharma, Coherus BioSciences, Dermavant, Dermira, DICE Therapeutics, Dow Pharma, Evelo Biosciences, Galderma, Gilead, GSK, Incyte, Janssen, Kyowa Kirin, Leo Pharma, Lilly, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sun Pharma, Takeda, and UCB; Honoraria: AbbVie, Acelyrin, Akros, Amgen, Aralez, Bausch Health/Valeant, Boehringer Ingelheim, Celltrion, Coherus BioSciences, Dermavant, DICE Therapeutics, Forbion, Galderma, Janssen, Kyowa Kirin, Leo Pharma, Lilly, Meiji Seika Pharma, Merck, Mitsubishi Pharma, Novartis, Pfizer, Reistone, Sanofi Genzyme, Sandoz, Sun Pharma, Takeda, UCB, vTv Therapeutics, and Xencor; Scientific officer: Akros, Anacor, Arcutis, DICE Therapeutics, and Kyowa Kirin; Steering committees: AbbVie, Amgen, Bausch Health/Valeant, Boehringer Ingelheim, Janssen, Kyowa Kirin, Lilly, Merck, Novartis, Pfizer, Regeneron, Reistone, and Sanofi Genzyme; Advisory boards: AbbVie, Amgen, Bausch Health/Valeant, Boehringer Ingelheim, Bristol Myers Squibb, DICE Therapeutics, Dow Pharma, Galderma, Janssen, Lilly, Merck, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB. **JV, EV, CD, and SB:** Employees and shareholders: Bristol Myers Squibb. **KH:** Consultant: Bristol Myers Squibb via Syneos Health. **BS:** Consultant (honoraria): AbbVie, Almirall, Amgen, Arcutis, Arena, Aristea, Asana, Boehringer Ingelheim, Bristol Myers Squibb, Connect Biopharma, Dermavant, Equillium, GSK, Immunic Therapeutics, Janssen, Leo Pharma, Lilly, Maruho, Meiji Seika Pharma, Mindera Health, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, UCB, Ventyx Biosciences, and vTv Therapeutics; Speaker: AbbVie, Janssen, Lilly, and Sanofi Genzyme; Co-scientific director (consulting fee): CorEvitas Psoriasis Registry; Investigator: AbbVie, Cara Therapeutics, CorEvitas Psoriasis Registry, Dermavant, Dermira, and Novartis. **DT:** Research support and principal investigator (clinical trials funds to institution): AbbVie, Almirall, Amgen, Biogen Idec, Bristol Myers Squibb , Boehringer Ingelheim, Galderma, GSK, Janssen-Cilag, Leo Pharma, Lilly, MSD, Novartis, Pfizer, Regeneron, Roche, Sandoz-Hexal, Sanofi, and UCB; Consultant: AbbVie, Almirall, Boehringer Ingelheim, Bristol Myers Squibb, Galapagos, Leo Pharma, Novartis, Pfizer, and UCB; Lecturer: AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Leo Pharma, Lilly, MSD, Novartis, Pfizer, Roche-Posay, Sandoz-Hexal, Sanofi, Target RWE, and UCB; Scientific advisory board: AbbVie, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Janssen-Cilag, Leo Pharma, Lilly, Morphosis, MSD, Novartis, Pfizer, Sanofi, and UCB. **AB:** Speaker (with honoraria): AbbVie, Bristol Myers Squibb, Lilly, Pfizer, Regeneron, and Sanofi; Scientific adviser (with honoraria): AbbVie, Abcentra, Aclaris, Affibody, Aligos, Almirall, Alumis, Amgen, AnaptysBio, Apogee, Arcutis, Arena, Aslan, Athenex, Bluefin Biomedicine, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, CTI BioPharma, Dermavant, EcoR1, Escient, Evelo Biosciences, Evommune, Forte Biosciences, Galderma, HighlightII Pharma, Incyte, InnoventBio, Janssen, Landos, Leo Pharma, Lilly, Lipidio, Merck, Nektar, Novartis, Pfizer, Rani, Rapt, Regeneron, Sanofi Genzyme, Spherix Global Insights, Sun Pharma, Takeda, TLL Pharmaceutical, TrialSpark, UCB, Union, Ventyx Biosciences, Vibliome, and Xencor; Clinical study investigator (institution has received clinical study funds): AbbVie, Acelyrin, Allakos, Almirall, Alumis, Amgen, Arcutis, Athenex, Boehringer Ingelheim, Bristol Myers Squibb, Concert, Dermavant, Evelo Biosciences, Evommune, Galderma, Incyte, Janssen, Leo Pharma, Lilly, Merck, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, UCB, and Ventyx Biosciences.

Presented at the Fall Clinical Dermatology Conference for PAs and NPs®; May 31-June 2, 2024; Scottsdale, AZ
This is an encore of the 2024 European Academy of Dermatology and Venereology Spring Symposium oral presentation

Email: aprilarmstrong@post.harvard.edu